Cycle Trading: Watching for a Biotech Breakout

Biotech's 2.41% gain on Monday rekindled my interest in this sector.


Biotech had a great multi-year run peaking in July, 2015.  It went on to print its mutli-year low in February of 2016.  And since then it has been consolidating below the 300 level.


A closer look reveals that Biotech has recently had multiple tests of the 300 level.


Notice how the 50 week MA is now aligned with the 200 week MA.


Since the last test of the 300 level was launched from support from the convergence of both the 50 week MA & the 200 week MA, a clear and convincing close above the 300 level should break Biotech out of its 16 month consolidation.

Note: All information on this page is subject to change. The use of this website constitutes acceptance of our user agreement. Please read our privacy policy and legal disclaimer. Opinions expressed at are those of the individual authors and do not necessarily represent the opinion of or its management. Risk Disclosure: Trading foreign exchange on margin carries a high level of risk, and may not be suitable for all investors. The high degree of leverage can work against you as well as for you. Before deciding to invest in foreign exchange you should carefully consider your investment objectives, level of experience, and risk appetite. The possibility exists that you could sustain a loss of some or all of your initial investment and therefore you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with foreign exchange trading, and seek advice from an independent financial advisor if you have any doubts.